Quarterly report pursuant to Section 13 or 15(d)

Revenue from Contracts with Customers - (Details)

v3.19.3
Revenue from Contracts with Customers - (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Aug. 31, 2017
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Disaggregation of Revenue [Line Items]          
Total revenue   $ 5,613,276 $ 4,074,786 $ 15,474,123 $ 13,342,699
Prescribed dietary supplements          
Disaggregation of Revenue [Line Items]          
Total revenue   2,318,000 2,097,000 5,909,000 5,767,000
Prescription drugs          
Disaggregation of Revenue [Line Items]          
Total revenue   3,195,000 1,978,000 9,465,000 7,279,000
License and other revenue          
Disaggregation of Revenue [Line Items]          
Total revenue $ 25,000,000 100,000 0 100,000 0
Sales force revenue          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 0 $ 0 $ 0 $ 296,875
Customer Concentration Risk | Sales Revenue | Major Customer Number One          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   32.00%   35.00%  
Customer Concentration Risk | Sales Revenue | Major Customer Number Two          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   31.00%   31.00%  
Customer Concentration Risk | Sales Revenue | Major Customer Number Three          
Disaggregation of Revenue [Line Items]          
Concentration risk percentage   27.00%   26.00%